Last update 01 Nov 2024

Hyperplasia of cervix

Last update 01 Nov 2024

Basic Info

Synonyms

CERVICAL HYPERPLASIA, Hyperplasia of cervix, Hyperplasia of cervix (finding)

+ [6]

Introduction-

Drugs associated with Hyperplasia of cervix

Human papillomavirus 11-valent recombinant vaccine (National Vaccine and Serum Institute)

Target-

Mechanism

Immunostimulants

Active Org.

Chengdu Institute of Biological Products [+2]

Originator Org.

Sinopharm Zhongsheng Biotechnology Research Institute Co., Ltd [+1]

Active Indication

Human Papillomavirus Infection

Inactive Indication

Condylomata Acuminata [+7]

Drug Highest PhasePhase 3

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Recombinant HPV-III(16/18/58) Vaccine(Beijing Health Guard Biotechnology)

Target-

Mechanism

Immunostimulants

Active Org.

Aihui Import and Export Process For Russia Heihe City Heilongjiang [+1]

Originator Org.

Beijing Health Guard Biotechnology, Inc.

Active Indication

Anal intraepithelial neoplasia [+11]

Inactive Indication-

Drug Highest PhasePhase 3

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Hyperplasia of cervix

CTR20212152 / Active, not recruitingPhase 3

评价重组三价人乳头瘤病毒（16/18/58 型）疫苗（大肠杆菌）在 9-26 岁中国健康女性中免疫原性和安全性的临床试验

[Translation] A clinical trial to evaluate the immunogenicity and safety of a recombinant trivalent human papillomavirus (type 16/18/58) vaccine (Escherichia coli) in healthy Chinese women aged 9-26 years

评价三价 HPV 试验疫苗在 9-14 岁（2 剂次）、9-17 岁（3 剂次）相比于 18-26 岁（3 剂次）中国女性中诱导免疫应答的非劣效性，并评价其免疫应答持久性和安全性等。

[Translation]

To evaluate the non-inferiority of the HPV trivalent vaccine in inducing immune responses in Chinese women aged 9-14 years (2 doses) and 9-17 years (3 doses) compared with those aged 18-26 years (3 doses), and to evaluate the durability and safety of the immune responses.

Start Date11 Oct 2021

Sponsor / Collaborator

Taizhou Tiande Pharmaceutical Co., Ltd.

[+2]

CTR20201795 / Active, not recruitingPhase 3

评价重组三价人乳头瘤病毒（16/18/58型）疫苗（大肠杆菌）在18-45岁中国女性的保护效力、安全性和免疫原性的多中心、随机、双盲、安慰剂对照的Ⅲ期临床试验

[Translation] A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the protective efficacy, safety and immunogenicity of a recombinant trivalent human papillomavirus (type 16/18/58) vaccine (Escherichia coli) in Chinese women aged 18-45 years

评价重组三价 HPV 疫苗（16/18/58 型）接种于 18-45 岁中国女性人群的保护效力。在 18-45 岁女性中接种三剂重组三价 HPV 疫苗（16/18/58 型）后可有效预防 HPV16、18 和 58 型别感染相关的高度宫颈异常（CIN 2/3）、原位腺癌（AIS）、浸润性宫颈癌、高级外阴上皮内瘤样病变（VIN 2/3）、高级阴道上皮内瘤样病变（VaIN 2/3）、外阴癌或阴道癌病变的发生。在 18-45 岁女性中接种三剂重组三价 HPV 疫苗（16/18/58 型）后可有效预防 HPV16、18 和 58 型别相关的 12 个月持续感染（PI12）。

[Translation]

To evaluate the protective efficacy of recombinant trivalent HPV vaccine (type 16/18/58) in Chinese females aged 18-45 years. Three doses of recombinant trivalent HPV vaccine (type 16/18/58) in females aged 18-45 years can effectively prevent the occurrence of high-grade cervical abnormalities (CIN 2/3), adenocarcinoma in situ (AIS), invasive cervical cancer, high-grade vulvar intraepithelial neoplasia (VIN 2/3), high-grade vaginal intraepithelial neoplasia (VaIN 2/3), vulvar cancer or vaginal cancer lesions associated with HPV16, 18 and 58 infection. Three doses of recombinant trivalent HPV vaccine (type 16/18/58) in females aged 18-45 years can effectively prevent 12-month persistent infection (PI12) associated with HPV16, 18 and 58.

Start Date17 Oct 2020

Sponsor / Collaborator

Taizhou Tiande Pharmaceutical Co., Ltd.

[+2]

CTR20201029 / CompletedPhase 2

随机盲法阳性对照设计评价11价重组人乳头瘤病毒疫苗接种于18-26岁中国女性的免疫原性和安全性II期临床试验

[Translation] A phase II randomized, blinded, positive-controlled clinical trial to evaluate the immunogenicity and safety of 11-valent recombinant human papillomavirus vaccine in Chinese women aged 18-26 years

免疫原性：评价18-26岁中国女性接种3剂试验疫苗后30天的免疫原性，并与阳性对照疫苗进行比较。安全性：评价18-26岁中国女性接种11价重组HPV疫苗（汉逊酵母）的安全性。

[Translation]

Immunogenicity: To evaluate the immunogenicity of the experimental vaccine 30 days after 3 doses in Chinese females aged 18-26 years and compare it with the positive control vaccine. Safety: To evaluate the safety of 11-valent recombinant HPV vaccine (Hansen yeast) in Chinese females aged 18-26 years.

Start Date20 Jun 2020

Sponsor / Collaborator

Sinopharm Zhongsheng Biotechnology Research Institute Co., Ltd

[+2]

100 Clinical Results associated with Hyperplasia of cervix

100 Translational Medicine associated with Hyperplasia of cervix

0 Patents (Medical) associated with Hyperplasia of cervix

140

Literatures (Medical) associated with Hyperplasia of cervix

01 Oct 2024·International Journal of Gynecology & Obstetrics

Developmental uterovaginal anomalies and histologic findings in transgender patients receiving gender‐affirming hysterectomies: A large case series

Article

Author: Lansdowne, Elisa ; Nguyen, Nghiem H. ; Sumida, Megan ; Tran, Christina ; Kim, Hoejeong ; Galzote‐Carino, Rosanna

AbstractObjectiveTo describe the incidence of uterovaginal anomalies and histologic findings in transgender and nonbinary (TGNB) patients seeking hysterectomies.MethodsAll patients receiving gender‐affirming hysterectomies between 2013 and 2023 were retrospectively reviewed. Primary outcomes included uterovaginal anomalies and histological findings. Multivariable logistic regressions were performed to evaluate relationships between variables of interest and whether they predict findings of uterovaginal anomalies, inactive endometrium, adenomyosis, leiomyoma, endometriosis, and cervical atrophy.Results278 patients received hysterectomies at an average age of 29.2 ± 8.3 years. Seven patients (2.5%) were found to have a developmental anomaly, including two bicornuate uterus (0.7%), two unicornuate uterus (0.7%), one septate uterus (0.4%), and two vaginal septum (0.7%). 60 patients (21.6%) were found to have inactive endometrium and 26 patients (9.4%) had cervical atrophy. Although 262 patients (94.2%) were on testosterone therapy, hormone duration was not a significant predictor of any uterine findings.ConclusionThis study describes uterovaginal anomalies in a large cohort of patients receiving gender‐affirming hysterectomies. Although long‐term testosterone use is commonly believed to be associated with endometrial and cervical atrophy, this study shows no such association.

01 Jan 2024·European journal of case reports in internal medicine

An Unusual Case of HHV-8 Negative, Idiopathic, Multicentric Castleman Disease Following Chronic Lymphocytic Leukaemia.

Article

Author: Fervaille, Caroline ; Depaus, Julien ; Sonet, Anne ; Vellemans, Hélène ; Krug, Benoit ; Sansen, Pierre-Yves ; Collinge, Elodie

BackgroundCastleman disease is a rare condition characterised by polytypic lymphocytes proliferation and lymphadenopathy generally with a benign course. Whereas high grade lymphoma (Richter syndrome) is a classical complication seen in chronic lymphocytic leukaemia with a poor outcome, benign conditions mimicking this entity are infrequent.Case descriptionWe describe the case of an 81-year-old Caucasian male who developed a human herpesvirus-8 (HHV-8)-negative, idiopathic multicentric Castleman disease (iMCD) following a treated Binet C chronic lymphocytic leukaemia (CLL). The clinical and radiological pattern raised initially the suspicion of a classical Richter transformation. Blood analysis showed auto-immune haemolytic anaemia and thrombocytopenia. He had normal immunoglobulin levels. The anatomopathological analysis of a cervical adenomegaly showed hypervascularisation and a polytypic plasmocytic proliferation compatible with a plasmocytic iMCD type. Interestingly, bone marrow examination showed reticuline fibrosis but, in the absence of anasarca or generalised oedema, we were not allowed to conclude to the diagnosis of a TAFRO syndrome. We excluded all other mimicking conditions, comprising haematological malignancies, infections, and auto-immune diseases He was first treated with corticosteroids with poor results but dramatically responded to tocilizumab (anti-Il6).ConclusionTo our knowledge, this the first case described of a Castleman disease following CLL and surprisingly mimicking Richter syndrome. Clinicians should be aware of this rare misleading condition.LEARNING POINTSCastleman disease can mimic a Richter transformation in a CLL patient.

01 Jan 2023·Wiadomosci lekarskie (Warsaw, Poland : 1960)

HYPERPLASIA OF THE FEMALE REPRODUCTIVE ORGANS IN UKRAINE.

Article

Author: Tolstanova, Galina O ; Artyomenko, Volodymyr ; Salmanov, Aidyn G ; Hladenko, Svitlana Y ; Koctjuk, Irina M ; Marchenko, Andrii O ; Korniyenko, Svitlana M

OBJECTIVEThe aim: To determine the role of infectious diseases as the cause of the Cervical, Ovarian and Breast hyperplasia in Ukraine.PATIENTS AND METHODSMaterials and methods: We conducted a retrospective multicenter cohort study from January 1st, 2020 to December 31st, 2022. This study included patients aged 20-59 years with a diagnosis of hyperproliferative pathology of the women reproductive organs without atypia, who sought medical care for hyperplastic processes admitted to the 12 hospitals from 9 regions of Ukraine.RESULTSResults: We had examined 4,713 women; out of which 81.1% met the clinical definition of female reproductive organs hyperplasia. Of all hyperplasia cases, most frequently recorded types were breast hyperplasia (41,7%), followed by cervical hyperplasia (31,1%) and ovarian hyperplasia (27,2%). History of Cervicitis (p<0.001), Vaginal cuff infection (p<0.001), Oophoritis (p<0.001), and Mastitis (p<0.001) were identified as independent risk factors of Cervical, Ovarian and Breast hyperplasia.CONCLUSIONConclusions: This study showed that surgical site infections after obstetric and gynecological operations are is the cause of Cervical, Ovarian and Breast hyperplasia. Therefore, early detection and treatment SSIs can reduce the risk of hyperplasia these organs.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Hyperplasia of cervix

Basic Info

Related

Analysis